Skip to main content

Targeting the purinergic system for disease-modification in epilepsy

Project description

Novel therapeutic targets in epilepsy

Epilepsy is a neurological condition that is characterised by seizures. Current therapies are ineffective in nearly 30 % of patients, necessitating the development of novel treatments. The EU-funded EpiPurines project is focusing on the purinergic signalling system, which is activated by nucleotides and nucleosides. Using disease animal models and induced pluripotent stem cells, scientists will investigate the outcome of targeting various receptors and enzymes implicated in the system's pathways. Results will help us understand the role of purinergic signalling in epileptogenesis and pave the way for new drugs that offer improved seizure control and suppression of epilepsy.

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Net EU contribution
€ 257 561,28
Address
Saint Stephen's Green 123
2 Dublin
Ireland
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Partners (1)

Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
United States
Net EU contribution
€ 0,00
Address
Rutgers Plaza 3
08901 New Brunswick
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 165 265,92